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A single-channel mechanism for 
pharmacological potentiation of 
GluN1/GluN2A NMDA receptors
Divyan A. Chopra1, Kiran Sapkota2, Mark W. Irvine3, Guangyu Fang3, David E. Jane3, Daniel T. 
Monaghan2 & Shashank M. Dravid1
NMDA receptors (NMDARs) contribute to several neuropathological processes. Novel positive allosteric 
modulators (PAMs) of NMDARs have recently been identified but their effects on NMDAR gating 
remain largely unknown. To this end, we tested the effect of a newly developed molecule UBP684 on 
GluN1/GluN2A receptors. We found that UBP684 potentiated the whole-cell currents observed under 
perforated-patch conditions and slowed receptor deactivation. At the single channel level, UBP684 
produced a dramatic reduction in long shut times and a robust increase in mean open time. These 
changes were similar to those produced by NMDAR mutants in which the ligand-binding domains 
(LBDs) are locked in the closed clamshell conformation by incorporating a disulfide bridge. Since the 
locked glutamate-binding clefts primarily contributes to receptor efficacy these results suggests that 
UBP684 binding may induce switch in conformation similar to glutamate LBD locked state. Consistent 
with this prediction UBP684 displayed greater potentiation of NMDARs with only the GluN1 LBD locked 
compared to NMDARs with only the GluN2 LBD locked. Docking studies suggest that UBP684 binds 
to the GluN1 and GluN2 LBD interface supporting its potential ability in stabilizing the LBD closed 
conformation. Together these studies identify a novel pharmacological mechanism of facilitating the 
function of NMDARs.
NMDA receptors (NMDARs) are ionotropic glutamate receptors widely expressed at central excitatory synapses 
and elsewhere. These receptors have critical roles in normal CNS function and in neuropathological disorders. 
NMDARs’ distinctive physiological properties (voltage-dependency, Ca2+ permeability, slow onset/offset) enable 
their essential roles in multiple processes such as experience-dependent plasticity and learning1. These proper-
ties, however, also contribute to their ability to cause cell death in various neuropathological conditions when 
over-activated and to cause symptoms of schizophrenia when under-activated. Consequently, modulators that 
can alter NMDAR function have considerable potential for treating various neurological and neuropsychiatric 
conditions. However, development of drugs acting at NMDARs has poorly translated into the clinical setting, pri-
marily due to unwanted side effects. NMDARs are heterotetrameric complexes composed of two glycine-binding 
GluN1 subunits and two glutamate-binding GluN2 subunits of which there are four subtypes (GluN2A-D) and 
sometimes incorporating a GluN3A or GluN3B subunit. Initial drug development focused on competitive agents, 
channel-blockers, and GluN2B-selective negative allosteric modulators (NAMs)1, 2. Recent drug development 
efforts have focused on NAMs with other patterns of subtype-selectivity and on positive allosteric modulators 
(PAMs) to potentiate NMDAR function3, 4.
The development of PAMs for NMDARs has gained significant interest since NMDAR potentiation is expected 
to be useful in treating schizophrenia and cognitive deficits3–6. Promising drug-like PAMs with varied patterns of 
subunit-selectivity have been identified7–13. However, the gating mechanism of these modulators remains poorly 
understood. We have recently identified UBP684 as a highly effective potentiator of all GluN1/GluN2 subtypes 
with a similar degree of potentiation at each subtype14. UBP684 is the naphthoic acid homologue of the phe-
nanthroic acid compound UBP6467. Compounds in this family, including UBP684, are allosteric modulators 
displaying either potentiating or inhibiting activity at NMDARs. They do not substitute for either L-glutamate 
or glycine and they do not activate the receptor nor act as competitive antagonists or voltage-dependent channel 
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blockers7. The activity of these compounds is retained in receptors with the N-terminal domain deleted. In chi-
meric experiments, the PAM activity was found to correspond to the S2 domain of the GluN2 subunit whereas 
negative allosteric activity correlated to the GluN2’s S1 domain7. Because UBP684 robustly potentiates NMDAR 
responses, we selected this compound for single channel mechanistic studies.
Here we have determined the effect of UBP684 on NMDAR function on heterologously expressed GluN1/
GluN2A receptors. We utilized previously known changes in gating mechanisms identified by mutational analysis 
to evaluate the potential conformational change induced by UBP684. Our studies suggest a novel mechanism of 
pharmacological potentiation of NMDARs wherein the ligand-binding domain (LBD) of the GluN2 subunit is 
stabilized in a closed, agonist-bound conformation.
Results
Effect of UBP684 on macroscopic currents is dependent on intracellular milieu. We first 
measured the EC50 of UBP684 in oocytes expressing GluN1/GluN2A subunits. UBP684 produced a maximal 
potentiation of 107 ± 21% with a EC50 of 28 ± 12 µM. Using fast concentration-jump experiments, we tested 
the effect of UBP684 on macroscopic GluN1/GluN2A whole-cell currents expressed in HEK293 cells under 
dialyzed (non-perforated) conditions. UBP684 (100 µM) was co-applied with glutamate (100 µM) and glycine 
(100 µM) (Fig. 1). UBP684 produced no effect on the peak response (p = 0.9327, N = 6, paired t-test, IUBP684/
Icontrol = 0.996 ± 0.077) but slowed the deactivation kinetics from 103.08 ± 27.63 ms in control condition to 
163.53 ± 41.58 ms (p = 0.0226). A transient rise in current was observed in the whole-cell recordings when the 
solution containing UBP684 and agonists was washed-out which is similar to effect produced by pregnenolone 
sulfate15, 16. We and others have shown that modulation of NMDAR responses by the endogenous allosteric 
modulator pregnenolone sulfate is affected by the mode of whole-cell recording16–18. Thus we performed perfo-
rated whole-cell recordings using gramicidin to test whether keeping the intracellular milieu intact would affect 
UBP684 modulatory actions. In perforated patch mode, UBP684 significantly increased the peak response by 
two-fold (IUBP684/Icontrol = 2.134 ± 0.204, p = 0.0207, N = 6,) and also slowed deactivation from 95.29 ± 21.31 
ms to 156.62 ± 36.54 ms (p = 0.0206). Additionally, a transient rise in whole-cell current was observed during 
drug wash-out. Thus the increase in deactivation kinetics and transient increase in current during wash-out 
was independent of the whole-cell mode. UBP684 alone did not have any effect on baseline of HEK293 cells 
expressing GluN1/GluN2A receptors (N = 3). We also conducted fast jump experiments in perforated whole-cell 
mode where glycine ± UBP684 were present in control solution and the cell was moved from control solution to 
one containing glycine and glutamate ± UBP684. We found that under these conditions UBP684 produced an 
Figure 1. UBP684 potentiates GluN1/GluN2A receptor responses and slows their deactivation kinetics. 
(A) UBP684 structure and PAM activity on GluN1/GluN2A receptors expressed in Xenopus oocytes. After 
obtaining a stable steady-state response to 10 µM L-glutamate and 10 µM glycine, application of 50 µM UBP684 
potentiates the agonist response (upper panel). Dose-response of UBP684 potentiation of GluN1/GluN2A 
receptor responses under saturating agonist conditions (300µM L-glutamate/300 µM glycine) is shown in the 
lower panel. (B) Whole-cell recordings (left panel) were obtained from HEK293 cells either in dialyzed (top 
row) or perforated mode (bottom row). Individual cell peak current and deactivation time in response to 
UBP684 application (right two panels). Using the fast concentration-jump technique, cells were exposed to 
a solution containing no drug and switched to a solution containing glutamate and glycine (black traces) or 
glutamate, glycine and UBP694 (red traces). UBP684 (100 µM) potentiated glutamate (100 µM) and glycine 
(100 µM) induced peak currents in the perforated condition, but not in the dialyzed condition. Slowing of the 
deactivation rate by UBP684 was observed under both modes. N = 6, *P < 0.05, paired t-test.
www.nature.com/scientificreports/
3Scientific RepoRtS | 7:  6933 | DOI:10.1038/s41598-017-07292-8
increase in peak currents (IUBP684/Icontrol = 1.413 ± 0.077, N = 5) as well as slowed the deactivation kinetics from 
88.0 ± 20.1 ms to 112 ± 21.5 ms (paired t-test, p = 0.0069).
UBP684 produces dramatic changes in the shut times which resemble effects of locked closed 
conformation of GluN2 ligand-binding domain. To determine the mechanism by which UBP684 
exerts its potentiating effects, we studied the effect of UBP684 on single-channel responses in the cell-attached 
patch clamp mode to replicate the gramicidin-perforated whole-cell mode as it has minimal effect on intracel-
lular milieu. Single-channel data obtained from one active channel was analyzed and fitted to kinetic models 
based on previous analysis of GluN1/GluN2A single channel activity19–22 (Fig. 2). Both control and UBP684 
patches demonstrated reasonably good fits with a scheme with five shut states and two open states as previously 
described23 suggesting this model provides a reasonable description of the receptor gating. These results demon-
strate that UBP684 does not affect the number of kinetic states that the receptor traverses before opening. Analysis 
of shut time constants revealed a dramatic shift in closed conformational states by UBP684. The time constants 
τ2, τ3 and τ4 were significantly reduced by UBP684 (Table 1). UBP684 also caused an increase in the area of τ2 
while reducing the area of the τ3, τ4 and τ5 shut time constants (Table 1). The shift in the shut time constants is 
in accordance with a reduction in the mean shut time in the presence of UBP684 (Fig. 3). Interestingly, such a 
dramatic shift in shut time has been observed previously by mutant receptors in which the LBDs are covalently 
kept in a closed conformation by disulfide bridges of engineered cysteines22, 24. In addition such effects are also 
produced by application of DTT which may also stabilize the closed conformation of the LBD25.
To directly compare the effects of UBP684 to the effects of having the LBD constrained in the closed confor-
mation in our experimental conditions, we studied the channel kinetics of single active channels from mutant 
NMDARs with cysteines introduced at N499C and Q686C in GluN1 (GluN1c) and K487C and N687C in GluN2A 
Figure 2. UBP684 induced changes in channel gating resemble effect of locking ligand-binding domain 
in closed conformation. Cell-attached patches containing one active channel were obtained with agonists 
alone (glutamate and glycine) (N = 7) or agonists plus UBP684 (N = 7) or from mutant GluN1c/GluN2Ac 
(N = 4) where the LBD was locked closed by engineered cysteine bridges. (A) Representative single-channel 
traces are shown. Single-channel recordings were filtered at 5 kHz (2 kHz for presentation) and digitized at 
20 kHz. (B) Shut time histograms were fitted with 5 exponential components. Fitting of composite shut time 
histograms is shown. Individual shut time histograms were fitted and the changes in time constants and their 
areas were compared. The fold change in the normalized time constants and area of time constants is shown. 
Data is compared using one-way ANOVA followed by Tukey’s post-hoc analysis. *P < 0.05, **P < 0.01 and 
***P < 0.001 compared to control. #P < 0.05, ###P < 0.001 compared to UBP684. SQRT stands for square root.
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(GluN2Ac) (Fig. 2) as previously described22. Several changes in the shut time constants and the areas of shut 
time were similar in the cysteine-substituted NMDARs and UBP684-potentiated NMDARs. ANOVA analysis of 
normalized time constants and area revealed similarities in the effect of UBP684 and mutant in reducing τ2 and 
τ3 and area of τ3 compared to control. Based on previous kinetic modeling of NMDAR activation these time con-
stants most likely represent changes in the GluN1 and GluN2 conformations (upon agonist binding) respectively 
before channel opening26, 27. Thus both UBP684 and locked-ligand binding domain receptor have strong effects 
on these and in particular τ3. Additionally, some differences were noted between UBP684 and GluN1c/GluN2Ac 
mutant. The most noteworthy difference among the two conditions is the change in τ4 which represents a fast 
desensitized state. Thus it appears that UBP684 also affects desensitization of the receptor. Accordingly, UBP684 
affected the rate constants for receptor traversing the desensitized states (Table 2).
To further understand the commonality between the actions of UBP684 and GluN1c/GluN2Ac mutant we 
assessed the effect of these manipulations on mean open time, mean shut time and open probability. As seen in 
Fig. 3, UBP684 robustly increases mean open time, reduces mean shut time and increases overall open proba-
bility. UBP684 increased the mean open time (±SEM) from 2.27 ± 0.28 ms (262,707 events; N = 7) in control 
patches to 5.09 ± 0.96 ms (457,992 events; N = 7, p = 0.0158, unpaired t-test). The mean shut time was reduced 
by UBP684; 20.05 ± 2.92 ms in control patches (263,098 events) to 4.13 ± 0.61 ms in UBP684 patches (458,009 
events, p < 0.001). Consequently, the open probability, measured over the entire length of recordings, was found 
to increase from 0.135 ± 0.030 in control patches to 0.542 ± 0.033 in UBP684 patches (p < 0.001). The amplitude 
of openings was unaffected by UBP684. The GluN1c/GluN2Ac mutant was found to significantly lower mean 
shut time compared to control (5.62 ± 1.86 ms, p = 0.0158, unpaired t-test; 135,773 events; N = 4) and increase 
open probability (0.370 ± 0.062, p < 0.001; Fig. 3), while the mean open time of the mutant receptor responses is 
between responses in the control and UBP684 conditions. The open time histogram fits indicated that the open 
time constant τ1 was significantly higher than control in both the UBP684-treated and the GluN1c/GluN2Ac 
mutant conditions (Table 1). There was also a shift in the area of time constants observed in the GluN1c/GluN2Ac 
mutant but this did not reach significance (Table 1).
Further maximum interval likelihood (MIL) fitting of single-channel data indicated that UBP684 affected sev-
eral gating steps to produce potentiation (Fig. 4). The slower gating steps were affected showing an increase in the 
forward rate constants, driving the receptor faster into the open states. This is in accordance with the changes seen 
with shut-time constants τ2 and τ3. The faster gating steps were also affected, keeping the receptor for a longer 
time in the open states, as seen with an increase in the open time constants τ1 and τ2. The changes in slower rate 
constants represent a larger conformational change in the LBD of the GluN2 subunit21, 27. The faster rate constants 
may represent a gating mechanism that occurs near the pore of the ion-channel28. The faster recovery from the 
desensitized states (D2-C2) implies that the receptor spends less time in the long-lived desensitized state. The 
rate constants obtained from MIL analysis were also able to satisfactorily predict the macroscopic wave forms for 
control and UBP684 (Fig. 4; Table 3) suggesting that the kinetic models predict channel behavior. Interestingly, 
our experimental data shows a small but significant increase in glutamate potency (Table 3) which may explain 
the slower deactivation. However, the macroscopic fitting suggests no change in apparent glutamate affinity and 
in fact a small decrease in glutamate affinity (Table 3). Additionally, simulations using the gating rates from MIL 
fits depicted in Fig. 4 with the same agonist binding and unbinding rates for control and UBP684 suggest that 
these models are sufficient to produce slower deactivation rate without shift in apparent agonist affinity. Thus one 
Time constants (ms) and areas (%) Condition
Open time
Control 
(N = 7) UBP684 (N = 7)
NR1c/NR2Ac 
(N = 4)
τ1 0.26 ± 0.03 0.86 ± 0.24* 0.73 ± 0.19*
τ2 2.76 ± 0.29 5.88 ± 1.08* 2.40 ± 0.25
a1 20 ± 3 16 ± 5 43 ± 17
a2 80 ± 3 84 ± 5 56 ± 17
Shut time
τ1 0.51 ± 0.05 0.42 ± 0.07 0.57 ± 0.12
τ2 5.06 ± 0.78 1.37 ± 0.18*** 2.40 ± 0.32*
τ3 18.7 ± 1.9 4.63 ± 0.4*** 11.3 ± 2.52*
τ4 62.3 ± 7.9 15.4 ± 1.3*** 70.2 ± 13.2
τ5 1189 ± 190 895 ± 151 1060 ± 314
a1 22 ± 3 27 ± 4 48 ± 5**
a2 25 ± 3 43 ± 7* 36 ± 3*
a3 42 ± 4 26 ± 4* 14 ± 4**
a4 10 ± 2 4 ± 1* 1.7 ± 1*
a5 0.5 ± 0.1 0.2 ± 0.04* 0.2 ± 0.1
Table 1. Time constants and area of the open and shut time histogram fits with Hidden Markov models. The 
histograms were fitted with a model containing 5 closed states and 2 open states. Mean ± SEM are presented. 
Comparison was performed using unpaired t-test in relation to control. *P < 0.05, **P < 0.01 and ***P < 0.001.
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Figure 3. UBP684 robustly affects the mean open time in addition to its effects on shut states. (A) Open time 
histograms were fitted with 2 exponential components. Fitting of composite open time histograms is shown. 
Individual open time histograms were fitted and the time constants and areas are presented in Table 1. UBP684 
(N = 7) increased (B) the mean open time and reduced (C) the mean shut time and lead to an overall increase in 
(D) open probability compared to control (N = 7). The GluN1c/GluN2Ac mutant (N = 4) shared the reduction 
in mean shut time and overall increase in open probability but did not lead to a significant increase in mean 
open time. *P < 0.05 and ***P < 0.001. SQRT stands for square root.
Rates (s−1)
Condition
Control N = 7 UBP684 N = 7 NR1c/NR2Ac N = 4
C1 → C2 110 ± 20 350 ± 20*** 145 ± 35
C2 → C1 80 ± 30 220 ± 45* 95 ± 25
C2 → C3 360 ± 60 1010 ± 160** 505 ± 85
C3 → C2 1030 ± 125 930 ± 245 615 ± 225
C3 → O1 700 ± 60 1330 ± 140** 1345 ± 200**
O1 → C3 1495 ± 185 530 ± 85*** 1040 ± 235
O1 → O2 1605 ± 370 825 ± 290 590 ± 425
O2 → O1 1075 ± 150 730 ± 110 735 ± 230
C1 → D1 1.7 ± 0.4 2.8 ± 0.7 1.9 ± 0.8
D1 → C1 1.0 ± 0.1 2.3 ± 0.8 1.3 ± 0.4
C2 → D2 11.8 ± 5.0 54.7 ± 11** 9.7 ± 4
D2 → C2 21.8 ± 4.5 49.2 ± 11* 15.9 ± 2
Table 2. Hidden Markov maximum interval likelihood fitting of the steady state currents. Idealized current 
records were fitted to the gating scheme as described in Fig. 4. All rates have units of s−1. Data are mean ± SEM 
from patches containing one active channel fitted individually. The rates were compared by unpaired t-test. 
*P < 0.05, **P < 0.01 and ***P < 0.001.
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possibility is that differences in the gating of agonist bound states may underlie the slower deactivation in the 
presence of UBP684 in addition to potential changes in agonist affinity.
In comparison to the previous analysis of GluN1c/GluN2Ac mutant22 we found similarity in the overall shift 
in the exponential components to left in the GluN1c/GluN2Ac compared to control. Similar effects are also noted 
for UBP684. However, there are differences in how this mutant affects time constants and gating rates in the 
two studies. This may arise due to differences in the control channel properties. For example, we found a lower 
mean open time of channels resulting in lower open probability which may explain differences in rate constants. 
Differences in pH, EDTA concentration and/or other constituents of the pipette solution may explain these dif-
ferences in channel behavior.
UBP684 potentiation is dependent upon GluN2 conformational flexibility. The LBD locked 
single-channels studies by Kussius and Popescu22 have demonstrated that GluN2 LBD-locked receptor open 
at higher efficacy and resembles a receptor with both GluN1 and GluN2 in LBD-locked conformation. Thus 
the observed UBP684-induced changes in single channel closed states are consistent with UBP684 potentiat-
ing by promotion of a conformation resembling or mimicking GluN2 LBD-locked state. To evaluate a possible 
difference between GluN1 and GluN2 conformational changes contributing to UBP684 potentiation, GluN1c/
GluN2AWT and GluN1WT/GluN2Ac were expressed in Xenopus oocytes and the NMDAR response to UBP684 
was determined. As previously reported22, GluN1c/GluN2AWT receptors gave responses to L-glutamate applied 
alone that were comparable to the application of glycine plus L-glutamate. Glycine by itself produced negligible 
responses. Conversely, GluN1/GluN2Ac receptors displayed a full response to glycine applied alone, but not with 
Figure 4. Kinetic mechanism describing the effects of UBP684 on GluN1/GluN2A receptor activation. (A) 
MIL fit of single-channel data to assess the gating mechanism underlying potentiation of UBP684 is shown. 
All rates are in sec−1. Bold numbers with asterisks denote the rates which were significantly different from 
glutamate/glycine control patches. Rates ± SEM are presented in Table 2. Data was analyzed using unpaired 
t-test. (B) Free-energy trajectories for the kinetic states in the different models are presented. The free energies 
of the active states for the mutant GluN1c/GluN2Ac is lower than control but is still higher than UBP684. Scale 
bar represents 1 kBT. (C) Macroscopic current profiles were obtained by whole-cell recordings (black traces). 
Cells were equilibrated to glycine ± UBP684 before exposing to glycine + glutamate ± UBP684 as detailed 
in Methods. Current profiles were fitted to the kinetic Markov models for control (green) and UBP684 (red) 
that included glutamate binding and unbinding steps. Except the desensitization rates and the agonist binding 
and unbinding rates all other rates were fixed to those depicted in the kinetic models. The models were able 
to accurately predict the activation and deactivation kinetics. Rates obtained from least squares fitting are 
presented in Table 3.
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L-glutamate alone. As shown in Fig. 5, UBP684 caused a significantly higher potentiation of GluN1c/GluN2AWT 
receptor responses (64 ± 13) than those of GluN1WT/GluN2Ac receptors (7 ± 1) (one-way ANOVA followed 
by Tukey’s test; p = 0.0012 and 0.0093 for GluN1WT/GluN2Ac compared to GluN1WT/GluN2AWT and GluN1C/
GluN2AWT respectively; N = 19–32).
Discussion
UBP684 a novel potentiator of the GluN1/GluN2A NMDARs. Recent studies have identified mul-
tiple, novel classes of allosteric modulators of NMDARs. These include both NAMs and PAMs with some that 
exhibit subtype selectivity. We used a novel PAM, UBP684 which is the naphthene homolog of the phenanthrene 
PAM UBP6467. UBP684 increased whole-cell current responses mediated by GluN1/GluN2A by approximately 
two-fold. This effect is dependent on the patch clamp recording mode used (perforated, not dialyzed). This find-
ing is similar to our previous observation with pregnenolone sulfate16. It will be of interest to study whether recep-
tor phosphorylation or other signaling pathways that can affect receptor function/conformation underlie this 
effect. It will be also of interest whether other potentiators produce similar intracellular milieu-dependent effects 
on channel properties. UBP684 slowed the deactivation rate of the receptor suggesting a potential difference in 
agonist interaction with the receptor. Under steady state conditions, the increase in open probability induced by 
UBP684 can be accounted for by both an increase in the mean open time of the receptor and a reduction in the 
mean shut time. The rightward shift in the open time constants by UBP684 (Fig. 3) as seen with the exponential 
fitting of the open time histograms suggest that UBP684 stabilizes the receptor’s open state for a longer duration 
in both the short-lived and long-lived open states accounting for the increase in mean open time. In addition, in 
the shut-time histograms with five exponential components, there is a dramatic leftward shift with the shoulder 
(or second peak in overall fitting seen with the control histogram, Fig. 2) significantly abolished in the presence 
of UBP684. This corresponds to greatly reduced τ2, τ3 and τ4 long-lived shut-time constants. Based on a previ-
ous model of NMDAR gating21, 26, 27, the reduction in the longer shut-time constants or a slower conformational 
change is suggestive of a role of GluN2 subunit in the potentiation seen by UBP684.
Gating effects of UBP684 in comparison to earlier potentiators and mutants. Previously ana-
lyzed potentiators of NMDARs have been found to enhance the efficacy of the receptor by either increasing the 
mean open time or by having subtle effects on the shut time components9, 16. In comparison, the dramatic left-
ward shift in shut time components induced by UBP684 is unique. To better understand the effect of UBP684, 
single-channel recordings using the GluN1c/GluN2Ac mutants were carried out. The LBD of the mutants were 
locked in a closed conformation, as if agonist was continuously bound22, 24. The shut-time histograms of this 
mutant receptor showed similarity with the histogram seen with UBP684, wherein the long-lived shut time con-
stants τ2 and τ3 are greatly reduced. It has been suggested that even in the presence of saturating concentrations 
of agonists (here glutamate), the LBD domain undergoes fluctuations between opening and closing of the cleft. 
Since locking of the GluN2 LBD, but not GluN1 LBD, increases receptor efficacy, these conformational changes 
in the cleft appear to be restricted to glutamate binding or a GluN2 gating step. In accordance with the attribu-
tion of the long-lived shut states (particularly τ3 in our case) to GluN2 conformational changes26, 27 there is a 
dramatic change in the duration and area of these states22. Thus, these results suggest that UBP684 influences 
the behavior of the receptor as if the LBD is constantly closed leading to a similarity in the shut time histogram 
to the LBD mutant. Using the LBD-locked mutants separately (GluN1c/GluN2A and GluN1/GluN2Ac), we find 
that UBP684 preferentially potentiates responses in the GluN1c/GluN2A receptor. Thus, consistent with the sin-
gle channel analysis, UBP684 appears to be enhancing conformational changes mediated by the GluN2 subunit 
more than that governed by the GluN1 subunit. A potential caveat is that the locked GluN2A-LBD construct may 
Rates
Experiment Macroscopic Fit
Control UBP684 Control UBP684
b+ — — 30 37
b− — — 25 84
d1+ — — 1.00 8.2
d1− — — 0.30 2.0
d2+ — — 22 165
d2− — — 46 107
Residual — — 2.67 × 10−6 8.85 × 10−5
glutamate EC50 or Kd 4.62 ± 0.32 3.12 ± 0.52 0.84 2.2
PO (peak) 0.54 ± 0.04 0.13 ± 0.03 0.55 0.13
MOT 2.276 5.093 2.1 0.453
Table 3. Fitting of macroscopic GluN1/GluN2A current response and effect of UBP684. The normalized 
residual sum of squares (indicated as Residual) were derived from the macroscopic fitting with the gating rates 
fixed to those derived from MIL fits (Fig. 4); the desensitization (d) and agonist binding (b+) and unbinding 
(b−) rates were set as free parameters. The agonist binding rates are in µM−1 s−1 and all other rate constants 
are s−1. The Kd is in µM and calculated as b−/b+. The desensitization rates were constrained to 5-fold ± rates 
derived from MIL fits (Fig. 4). Open probability (Po), mean open time (MOT).
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be maximally open such that potentiation by any mechanism is obscured. However, further potentiation of the 
GluN1c/GluN2Ac receptor’s activity can be seen by cysteine modification of receptors including GluN1 A652C 
which leads to maximal activation24. Also, the conclusion that activity of the GluN1c/GluN2Ac construct is not 
saturated is consistent with the greater mean open time in the presence of UBP684 than in the GluN1c/GluN2Ac 
construct. Since wildtype receptors with UBP684 display a longer mean open time than GluN1c/GluN2Ac recep-
tors and yet UBP684 potentiation is largely blunted in this construct, it is possible that UBP684 promotes a state 
of greater efficacy than seen in GluN1c/GluN2Ac construct, but locking the LBD prevents the ability of UBP684 
to promote greater efficacy.
UBP684 is likely to have additional effects since it enhances open time stability leading to longer open states 
(Fig. 3), changes the time constants and rates for desensitized states (Figs 2 and 4) and has more robust effects 
on the forward rate constants (C1-C2, C2-C3) and reverse rate constant (O1-C3) compared to GluN1c/GluN2Ac 
(Fig. 4). In relation to changes in desensitization rates, the location of UBP684 at the LBD interface based on 
docking analysis (Fig. 5) has similarity to the proposed mechanism of cyclothiazide in inhibiting AMPA receptor 
desensitization29. Additionally, this location can influence receptor conformations which are not affected by the 
GluN2-ligand-locked mutant. One interpretation of the changes in rate constants and free-energy trajectories 
may be that the GluN1c/GluN2Ac state is an intermediary state in the effects of UBP684 which accelerate the for-
ward rates to channel opening with greater efficacy. While the PAM UBP684 appears to stabilize the open channel 
states, the structurally related NAM, 2-naphthoic acid, stabilizes the closed states30. These agents have opposite 
effects on mean open time as well as on mean shut time consistent with their PAM and NAM activities. They also 
have generally opposite effects on the time spent in the different closed states. UBP684 decreases the area of the 3 
slowest shut states while increasing the area of the first two shut states and conversely 2-naphthoic acid increases 
the area of three longest shut states and decreases the area of the shortest shut state30. One of the caveats in our 
study is that the single channel data is correlational between the effect of UBP684 and the effect of the LBD locked 
mutant. Although, the testing in oocytes addresses this caveat, it will be important to directly test the loss of fur-
ther change in single channel behavior when UBP684 is tested in the LBD locked mutant.
Figure 5. UBP684 potentiation is dependent on GluN2 LBD flexibility. (A) Current traces showing the effect 
of UBP684 on wildtype, GluN1 LBD-locked (GluN1C/GluN2WT) or GluN2 LBD-locked (GluN1WT/GluN2C) 
receptors. (B) UBP684 potentiated wildtype and GluN1 LBD-locked receptors but not GluN2 LBD-locked 
receptors (one-way ANOVA followed by Tukey’s test; P = 0.0012 and 0.0093 for GluN1WT/GluN2Ac compared 
to GluN1WT/GluN2AWT and GluN1C/GluN2AWT respectively; N = 19–32). (C) Molecular modeling of UBP684 
binding to the GluN1/GluN2A receptor LBD dimer. Top: UBP684 (space filled) is shown docked into the 
GluN1/GluN2A LBD intersubunit interface. Modeling suggests that the carboxylic acid group of UBP684 
interacts with positively charged residues on the top of the LBD away from the transmembrane domains and 
near the N-terminal domains. The alkyl side chain terminates near the LBD hinge region near GluN1 Y535 
shown in green. Bottom: The same docking of UBP684 is shown rotated 90° in the horizontal plane with the 
GluN1 LBD removed and GluN1’s Y535 shown for reference.
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The UBP PAMs do not bind at the orthosteric glutamate or glycine binding sites, nor do they behave like 
channel blockers and they do not act by binding to the N-terminal domain7. These findings are consistent with 
chimeric studies which indicate that the second segment (S2) domain of the GluN2 LBD is critical for UBP-PAM 
activity7. By analogy to AMPA receptor potentiation by CZX61431, PAM binding at the LBD dimer interface 
near the hinge region of the LBD clamshell structure potentially stabilizes the agonist-bound conformation. Our 
molecular docking studies show that UBP684 can be docked into this space in GluN1/GluN2A subunits with 
the alkyl chain of UBP684 terminating close to the hinge region. This site is similar to that recently described by 
crystalography for GluN1/GluN2A potentiator GNE-690113. It is also possible, however, that UBP684, is acting 
near the distal S2/S2-M3 linker region near the activation gate which is present on the M3 segment of the TMD 
in a manner similar to that proposed for neurosteriods32. UBP684 is not likely to be binding where spermine or 
PYD-106 bind as these involve the N-terminal domain33, 34 which is unnecessary for UBP-PAM activity7.
Conclusion
Our results reveal a unique gating mechanism for pharmacological potentiation of NMDARs. We have used 
a correlational approach to predict the potential conformational changes induced by a novel GluN1/GluN2A 
potentiator, however further mutational and structural studies are required to identify the precise site of action of 
UBP684 and other PAMs which may have similar site of action. It will be interesting to test whether GNE-690113 
produces similar gating effects which would demonstrate a conserved mechanism across different families of 
potentiators. Our results define a mechanism of action for a novel class of NMDA receptor potentiators and sug-
gest a structural basis that should facilitate further drug development of NMDAR PAMs for multiple therapeutic 
applications.
Materials and Methods
Xenopus oocyte physiology. To express NMDA receptors in Xenopus oocytes, cDNA plasmids encod-
ing the NMDAR1a subunit (GluN1a) (generously provided by Dr. Shigetada Nakanishi, Kyoto, Japan). GluN2A 
(generously provided by Dr. Peter Seeburg, Heidelburg, Germany), and GluN1 and GluN2A constructs with 
cysteine substitutions at N499C and Q686C in GluN1 (hereafter GluN1c) and for K487C and N687C in GluN2A 
(hereafter GluN2Ac)22 (generously provided by Dr. Gabriela Popescu, University of Buffalo) were linearized with 
Not I (GRIN1a, GRIN1c, GRIN2Ac) or EcoR I (GRIN2A) and transcribed in vitro with T7 RNA polymerase using 
the mMessage mMachine transcription kits (Ambion, Austin, TX, USA).
Oocytes from mature female Xenopus laevis (Xenopus One, Ann Arbor, MI, USA) were removed and isolated 
using procedures approved by the University of Nebraska Medical Center’s Institutional Animal Care and Use 
Committee in compliance with the National Institutes of Health guidelines. NMDA receptor subunit RNAs were 
dissolved in sterile distilled H2O. GluN1a and GluN2 RNAs were mixed in a molar ratio of 1:1–3. 50 nl of the final 
RNA mixture was microinjected (15–30 ng total) into the oocyte cytoplasm. Oocytes were incubated in ND-96 
solution for 1–5 days at 17 °C prior to electrophysiological assay.
Electrophysiological responses were measured using the two electrode voltage clamp model OC-725B 
amplifier (Warner Instruments, Hamden, Connecticut,). The recording buffer contained 116 mM NaCl, 2 mM 
KCl, 0.3 mM BaCl2 and 5 mM HEPES, pH 7.4. Response magnitude was determined by the steady plateau 
response elicited by bath application of 10 µM L-glutamate plus 10 µM glycine and held at a membrane potential 
of −60 mV. After obtaining a steady-state response to agonist application, test compounds were bath applied 
(Automate Scientific 16-channel perfusion system) and the responses were digitized for analysis (Digidata 1440 A 
and pClamp-10, Molecular Devices). Dose-response relationships were fit using GraphPad Prism, ISI Software, 
using a nonlinear regression to calculate EC50 and % maximal effect.
Expression of recombinant NMDARs. Human embryonic kidney (HEK) 293 cells were transiently trans-
fected with cDNA coding for GluN1 and GluN2A subunits or GluN1c and GluN2Ac subunits22 and green fluo-
rescent protein (GFP) in the ratio of 1:2:0.5 using ViafectTM reagent (Promega Corporation, Madison, WI) as 
previously described16. Electrophysiology experiments were performed 16–48 hours after transfection.
Mammalian cell electrophysiology. Whole-cell and single-channel recordings were obtained from trans-
fected HEK 293 cells at room temperature (22–25 °C) in an external solution containing (in mM) 150 NaCl, 3 
KCl, 10 HEPES, 0.02 mM EDTA and 6 mannitol. Recordings were conducted in the absence of nominal extra-
cellular CaCl2. The external pH was adjusted to 7.4 with NaOH. Cells or patches were exposed to either 100 μM 
glutamate and 100 μM glycine (control patches) or 100 μM glutamate, 100 μM glycine and 100 μM UBP684. For 
whole-cell recordings, agonists and UBP684 were added to the extracellular solution. For cell-attached recordings 
the external solution served as pipette solution and agonists/UBP684 were include in this solution. In case of 
perforated whole-cell patch-clamp recordings the pipette solution was supplemented with 20 µg/ml of gramici-
din. Whole-cell configuration after giga-ohm seal was reached typically within 10–15 minutes. Recordings were 
obtained using a Axopatch 200B amplifier (Axon Instruments/Molecular Devices) and digitized with pCLAMP 
10 software (Axon Instruments/Molecular Devices). Whole-cell recordings were obtained at −70 mV, filtered at 
2 kHz, and digitized at 5 kHz. For cell-attached recordings a potential (Vm) of +70 mV was applied and data were 
filtered at 5 kHz (−3 dB, 8-pole Bessel) and digitized at 20 kHz. Single-channel amplitude was not corrected for 
junction potential.
The internal solution used for whole-cell recordings consisted of (in mM) 110 cesium gluconate, 30 CsCl2, 
5 HEPES, 4 NaCl, 0.5 CaCl2, 2 MgCl2, 5 BAPTA, 2 Na2ATP, and 0.3 Na2GTP (pH 7.3). Rapid perfusion for 
whole-cell concentration jumps was achieved with a two-barreled theta glass pipette controlled by a piezoelectric 
translator (Burleigh). The solution exchange times for 10–90% solution were typically ~1–2 ms for open tip. Thus 
for the whole-cell the complete exchange of solution with take a few milliseconds. Thus the exchange time is not 
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a limiting factor to determine the deactivation time constants. Cell was exposed to control solution with no drugs 
followed rapidly by a solution containing agonists ± UBP684. Drug application was typically for 2.5 s during each 
15 s sweep.
Data processing and kinetic modeling. Upward deflections were considered as open state during 
cell-attached recordings. Recordings containing a single active channel were idealized using QUB software (www.
qub.buffalo.edu) as previously described23, 35. In addition to lack of visual observation of two simultaneous open-
ing, to confirm the presence of only one active channel in our patches we utilized an approximation method36 that 
we have previously detailed using GluN1/GluN2C receptors which have a very lower open probability (0.011)23. 
Based on this approximation we are confident that the patches utilized in our studies contained only one active 
channel. The idealized data was used for maximum interval likelihood fitting (MIL; ref. 36). A 120 μs dead time 
was imposed using QUB. The C5O2 model consisting of 3 closed and 2 open states in linear configuration and 
two desensitized states emerging from C1 and C2 respectively provided the best fit to the single channel data 
based on the log likelihood values compared to other models including the C4O2 model with four instead of five 
closed states and a model where the receptor can transition to either a fast or slow gating step as described pre-
viously35. The mean open time, mean shut time and open probability was obtained from the idealized data using 
ChanneLab (www.synaptosoft.com), with an imposed dead time of 120 μs. Peak and steady state responses and 
deactivation, and desensitization time course for whole-cell recordings were analyzed using Clampfit (pClamp 
10.2).
Macroscopic response fitting. For macroscopic fitting, whole-cell responses to glutamate application 
on cells pre-equilibrated with glycine or glycine + UBP684 were obtained. The average control and UBP684 
wave forms were normalized with the peak currents to be equal to the respective open probabilities (Fig. 3). 
Aggregated Markov models were fitted to individual wave forms using a nonlinear least sum of squares algorithm 
(ChanneLab). Glutamate binding and unbinding rates and desensitization rates were set as free parameters and 
the other gating steps were fixed to those obtained using MIL fits to single-channel data (Fig. 4).
Statistical Analysis. All values are expressed as mean ± SEM. Data were compared using paired t-test for 
macroscopic current profiles and unpaired t-test and one-way ANOVA for the cell-attached patches. Values of 
P ≤ 0.05 were considered significantly different.
Data availability. All relevant data are available from the authors.
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